Skip to content Skip to footer
Subscribe Now

INSIGHTS+

PharmaShots' Key Highlights of Fourth Quarter 2022
PharmaShots’ Key Highlights of Fourth Quarter 2022
Shots: The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…
December 29, 2022
Insights+ EMA Marketing Authorization of New Drugs in November 2022
Insights+: EMA Marketing Authorization of New Drugs in November 2022
Shots: The EMA approved 4 New Chemical Entity (NCE) and 4 Biologic Drugs in November 2022, leading to treatments for patients and advances in the healthcare industry In November 2022, the major highlights drugs were Skyrizi's approval for active crohn's disease, Beyfortus for RSV lower respiratory tract disease PharmaShots has compiled a list of a…
December 28, 2022
Top Performing Drug of 2021 – Opdivo (December Edition)
Top Performing Drug of 2021 – Opdivo (December Edition)
Active Ingredient: Nivolumab  Strength: 40 mg/4 mL, 100 mg/10 mL, & 240 mg/24 mL solution in a single-dose vial  Dosage Form: Injection  Mechanism of Action: Programmed cell death-1 receptor antagonists (PD-1)  First Approval: US (22 Dec 2014), EU (19 Jun 2015)   Revenue Analysis of Opdivo BMS’ Opdivo gives tough competition to other drugs in the…
December 22, 2022
Disease of the Month: AIDS
Disease of the Month: AIDS
“Putting Ourselves to the Test: Achieving Equity to End HIV”  -Theme of the year 2022  Introduction: HIV/AIDS is one of the top 10 cause of mortality. It is a chronic, epidemic disease caused by human immunodeficiency virus (HIV), a virus that infect WBC’s CD4 T-cell of the immune system. HIV, a type of retrovirus that isn't…
December 20, 2022
Insights+ The US FDA New Drug Approvals in November 2022
Insights+: The US FDA New Drug Approvals in November 2022
The US FDA approved 1 NDAs and 6 BLA in November 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 73 novel products in 2022 In November 2022, the major highlights drugs were Imfinzi (durvalumab) + Imjudo (tremelimumab) approval for metastatic non-small cell lung cancer, Elahere for…
December 15, 2022
Insights+ Key Biosimilars Events of November 2022
Insights+ Key Biosimilars Events of November 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of November, Samsung Bioepis presented two P-III studies results…
December 1, 2022
Top Performing Drug of 2021 – Xarelto (November Edition)
Top Performing Drug of 2021 – Xarelto (November Edition)
Active Ingredient: rivaroxaban  Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg  Dosage Form: Tablets  Mechanism of Action: Factor Xa inhibitors  First Approval: US (1 Jul 2011), EU (30 Sep 2008)  Revenue Analysis of Xarelto1  Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…
November 24, 2022
Insights+ EMA Marketing Authorization of New Drugs in October 2022
Insights+: EMA Marketing Authorization of New Drugs in October 2022
The EMA approved 2 Biologic Drugs in October 2022, leading to treatments for patients and advances in the healthcare industry In October 2022, the major highlights drugs were Yescarta approval for diffuse large B-cell lymphoma and high-grade B-cell lymphoma, and Adtralza for atopic dermatitis PharmaShots has compiled a list of a total of 2 new…
November 23, 2022
Insights+ The US FDA New Drug Approvals in October 2022
Insights+: The US FDA New Drug Approvals in October 2022
The US FDA approved 1 NDAs and 2 BLA in October 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 66 novel products in 2022 In October 2022, the major highlights drugs were Tecvayli’s approval for relapsed or refractory multiple myeloma, Furoscix for congestion in chronic heart…
November 17, 2022
Disease of the Month: Epilepsy
Disease of the Month: Epilepsy
INTRODUCTION Also known as seizure disorder, epilepsy is a non-communicable chronic disorder of the brain and is the fourth most common neurological disease globally. It is a central nervous system (CNS) disorder characterized by recurrent episodes of seizures that are short changes in normal brain activity which led to brief incidences of involuntary movements either…
November 16, 2022
Load more